ArticleFrontiers in immunology2023

Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors.

Jian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.